CA2861442C - Derives piperazinyl pyrimidines, procede de preparation et utilisation associees - Google Patents

Derives piperazinyl pyrimidines, procede de preparation et utilisation associees Download PDF

Info

Publication number
CA2861442C
CA2861442C CA2861442A CA2861442A CA2861442C CA 2861442 C CA2861442 C CA 2861442C CA 2861442 A CA2861442 A CA 2861442A CA 2861442 A CA2861442 A CA 2861442A CA 2861442 C CA2861442 C CA 2861442C
Authority
CA
Canada
Prior art keywords
compound
formula
group
amino
pyrimidin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2861442A
Other languages
English (en)
Other versions
CA2861442A1 (fr
Inventor
Song Li
Ying Wang
Junhai Xiao
Dalong Ma
Hongwei GONG
Hui QI
Lili Wang
Xiaomei LING
Zhibing Zheng
Yang Zhang
Wu Zhong
Meina LI
Yunde Xie
Enquan XU
Xingzhou Li
Jing Ma
Guoming Zhao
Xinbo Zhou
Xiaokui Wang
Hongying Liu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Peking University
Institute of Pharmacology and Toxicology of AMMS
Original Assignee
Peking University
Institute of Pharmacology and Toxicology of AMMS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Peking University, Institute of Pharmacology and Toxicology of AMMS filed Critical Peking University
Publication of CA2861442A1 publication Critical patent/CA2861442A1/fr
Application granted granted Critical
Publication of CA2861442C publication Critical patent/CA2861442C/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/50—Three nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Otolaryngology (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

L'invention concerne des dérivés pipérazinyl pyrimidines de formule I ayant un antagonisme de CCR4, un procédé de préparation, une composition pharmaceutique et son utilisation dans la préparation d'un médicament. Le médicament est utile pour le traitement et la prévention de maladies associées à CCR4.
CA2861442A 2012-01-16 2013-01-15 Derives piperazinyl pyrimidines, procede de preparation et utilisation associees Active CA2861442C (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201210011263.3 2012-01-16
CN201210011263.3A CN103204816B (zh) 2012-01-16 2012-01-16 哌嗪基嘧啶类衍生物及其制备方法和用途
PCT/CN2013/070469 WO2013107333A1 (fr) 2012-01-16 2013-01-15 Dérivés pipérazinyl pyrimidines, procédé de préparation et utilisation associées

Publications (2)

Publication Number Publication Date
CA2861442A1 CA2861442A1 (fr) 2013-07-25
CA2861442C true CA2861442C (fr) 2018-11-06

Family

ID=48752248

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2861442A Active CA2861442C (fr) 2012-01-16 2013-01-15 Derives piperazinyl pyrimidines, procede de preparation et utilisation associees

Country Status (10)

Country Link
US (1) US9493453B2 (fr)
EP (1) EP2805947B1 (fr)
JP (1) JP6039691B2 (fr)
KR (1) KR101880965B1 (fr)
CN (1) CN103204816B (fr)
AU (1) AU2013211414B2 (fr)
CA (1) CA2861442C (fr)
ES (1) ES2621901T3 (fr)
RU (1) RU2608315C2 (fr)
WO (1) WO2013107333A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201700814D0 (en) 2017-01-17 2017-03-01 Liverpool School Tropical Medicine Compounds
CN115466244B (zh) * 2021-06-10 2024-08-02 武汉伯瑞恒医药科技有限公司 趋化因子受体ccr4拮抗剂、其中间体、制备方法、药物组合物和应用
KR20230149729A (ko) * 2022-04-19 2023-10-27 케모센트릭스, 인크. Ccr4 길항제

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2341925A1 (de) 1973-08-20 1975-03-06 Thomae Gmbh Dr K Neue pyrimidinderivate und verfahren zu ihrer herstellung
FR2503162A1 (fr) * 1981-04-07 1982-10-08 Pharmindustrie Nouveaux derives de piperazino-2 pyrimidine, procedes pour leur preparation et leur utilisation comme medicaments ou comme intermediaires pour la fabrication de medicaments
JPS62142177A (ja) * 1985-12-13 1987-06-25 Teikoku Chem Ind Corp Ltd ２−ピペラジニルピリドピリミジン化合物
LU86695A1 (fr) * 1986-12-01 1988-07-14 Oreal Nouveaux derives de piperazinyl-1 pyrimidine,leur preparation et leur application en therapeutique et cosmetique
US20020137755A1 (en) 2000-12-04 2002-09-26 Bilodeau Mark T. Tyrosine kinase inhibitors
US7202249B2 (en) * 2002-08-27 2007-04-10 Bristol-Myers Squibb Company Antagonists of chemokine receptors
PL1673092T3 (pl) 2003-10-17 2008-01-31 4 Aza Ip Nv Pochodne pterydyny podstawione heterocyklem i ich zastosowanie w leczeniu
WO2005082865A1 (fr) 2004-02-27 2005-09-09 Astellas Pharma Inc. Dérivé de pyrimidine bicyclique fondu
JP2007217282A (ja) * 2004-03-04 2007-08-30 Astellas Pharma Inc 置換ピリミジン誘導体
NZ564222A (en) * 2005-06-14 2011-10-28 Taigen Biotechnology Co Ltd Pyrimidine compounds
WO2007063934A1 (fr) * 2005-12-02 2007-06-07 Mitsubishi Tanabe Pharma Corporation Compose heterocyclique alicyclique
DK2268635T3 (en) * 2008-04-21 2015-09-14 Taigen Biotechnology Co Ltd Heterocyclic Compounds
CN101914142A (zh) * 2010-07-12 2010-12-15 中国科学院化学研究所 具有电位势梯度的肽核酸纳米异质结及其制备方法与应用

Also Published As

Publication number Publication date
AU2013211414B2 (en) 2017-08-10
KR101880965B1 (ko) 2018-07-23
US9493453B2 (en) 2016-11-15
JP2015506936A (ja) 2015-03-05
CN103204816A (zh) 2013-07-17
EP2805947A4 (fr) 2015-05-27
HK1199032A1 (en) 2015-06-19
RU2014133518A (ru) 2016-03-10
CN103204816B (zh) 2016-04-27
JP6039691B2 (ja) 2016-12-07
ES2621901T3 (es) 2017-07-05
WO2013107333A1 (fr) 2013-07-25
AU2013211414A1 (en) 2014-08-28
KR20140121441A (ko) 2014-10-15
US20150126500A1 (en) 2015-05-07
EP2805947A1 (fr) 2014-11-26
RU2608315C2 (ru) 2017-01-17
EP2805947B1 (fr) 2017-02-22
CA2861442A1 (fr) 2013-07-25

Similar Documents

Publication Publication Date Title
JP5690715B2 (ja) ケモカイン受容体調節因子
CA2441501C (fr) Inhibiteurs de rho-kinase
US20080261978A1 (en) Chemokine receptor modulators
US20220388985A1 (en) Targeted protein degradation of parp14 for use in therapy
CN114728170B (zh) 对核受体具有活性的化合物
CA2861442C (fr) Derives piperazinyl pyrimidines, procede de preparation et utilisation associees
EP4171565A2 (fr) Pyridine-1,5-diones présentant une activité d'inhibition de mnk et leurs méthodes d'utilisation
CN112851583B (zh) 新型苯并氮杂䓬类化合物、组合物及其用途
HK1199032B (en) Piperazinyl pyrimidine derivatives, preparation method and use thereof
CN101747327B (zh) 芳酰胺基噻唑类衍生物及其制备方法和用途
US20260125362A1 (en) Targeted protein degradation of parp14 for use in therapy
WO2023225601A2 (fr) Ripk2 et inhibiteurs de nod
CN102076682A (zh) 五元环化合物
HK1156619A (en) Chemokine receptor modulators

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20161027

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 12TH ANNIV.) - STANDARD

Year of fee payment: 12

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241216

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20241216

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20241216

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 13TH ANNIV.) - STANDARD

Year of fee payment: 13

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20251218

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20251218